TNO155 是具有口服活性野生型SHP2的选择性变构抑制剂 (IC50= 0.011 μM)。它有研究 RTK 依赖性恶性肿瘤（尤其是晚期实体瘤）的潜力。

TNO155 is a protein tyrosine phosphatase (PTP) non-receptor type 11 (SHP2; src homology region 2 domain phosphatase; PTPN11) inhibitor(IC50 : 0.011 μM),with potential antineoplastic activity.

1801765-04-7

C18H24ClN7OS

421.95

DMSO:185mg/ml (438.44 Mm),Need ultrasonic
Powder: -20°C for 3 years
In solvent: -80°C for 2 years